50 results about "End systole" patented technology

The invention comprises a method and apparatus for generating a synthetic echocardiographic image. The method comprises first obtaining, for a plurality of pathologically similar reference hearts, a reference echocardiographic image of each reference heart at end-systole and at end-diastole. Next, the coupled epicardial and endocardial borders are identified in each echocardiographic image. An epicardial/endocardial border pair is then modeled from the identified borders. The method then locates a plurality of predetermined features in the reference echocardiographic images. The predetermined features are then located in the subject echocardiographic image from the location of the predetermined features in the reference echocardiographic images. The modeled epicardial/endocardial border pair is then mapped onto the subject echocardiographic image relative to the location of the predetermined features in the subject echocardiographic image. The apparatus generally comprises an echocardiographic machine for obtaining the echocardiographic images that are then processed by a computing system. In one aspect of the invention, the invention comprises such a computing system programmed to perform the autonomous portions of the method. In another aspect, the invention comprises a program storage medium encoded with instructions that perform the autonomous portions of the method when executed by a computer.

A method includes receiving a multi-phase axial cardiac dataset, receiving a selection of a phase from a user, when the received selection is systole, generating an endocardial volume of a left ventricle at an end systole phase without further user intervention, and when the received selection is diastole, generating an endocardial volume of the left ventricle at an end diastole phase without further user intervention.

An apparatus for treating a heart of a patient includes a first lead and at least a second lead for pacing the heart adapted to be in electrical communication with the heart. The apparatus includes a microcontroller in communication with the first and second leads which triggers the first lead at either different times or the same time from when the microcontroller triggers the second lead. Alternatively, the apparatus includes a microcontroller in communication with the first and second leads that determines heart volume, including stroke volume, end-systolic volume, and calculated values including ejection fraction, from admittance from signals from the first and second leads and uses the admittance as feedback to control heart volume ejected, as measured by stroke volume, calculated values such as ejection fraction, and control end-systolic volume, with respect to the first and second leads. A method for treating the heart of a patient.

A system and method to acquire 3D ultrasound-based images during the end-systole and end end-diastole time points of a cardiac cycle to allow determination of the change and percentage change in left ventricle volume at the time points.

The ultrasonic diagnostic system estimates a desired time phase or one cycle period of a moving region (e.g., a heart) that repeats contraction and relaxation cyclically and which can be specified by a presystole, an end systole, a prediastole, an end diastole, and other clinical characteristics for one cycle of the moving region on the basis of the velocity information on multiple positions of the moving region which is obtained for each time phase. More specifically, assuming that, for example, the end systole phase=a time phase in which the myocardial velocity comes to zero or close to zero, the system calculates |myocardial velocity| for each time phase in a predetermined period, and estimates a time phase in which this value comes closest to zero as an end systole phase.

An ultrasound diagnosis apparatus which performs ultrasonic diagnosis with respect of a fetal heart. An area change measurement section calculates an area of a specific heart chamber (left ventricle) in the fetal heart in frame units. Further, the area change measurement section generates a graph representing the area which is calculated in frame units. The maximum value and the minimum value are specified in the graph to thereby specify end-diastole and end-systole. Based on this information, a heart rate and a cardiac cycle with regard to the fetal heart are calculated. Further, an ejection fraction is also calculated from an end-diastolic area and an end-systolic area.

Impedance, e.g. sub-threshold impedance, is measured across the heart at selected cardiac cycle times as a measure of chamber expansion or contraction. One embodiment measures impedance over a long AV interval to obtain the minimum impedance, indicative of maximum ventricular expansion, in order to set the AV interval. Another embodiment measures impedance change over a cycle and varies the AV pace interval in a binary search to converge on the AV interval causing maximum impedance change indicative of maximum ventricular output. Another method varies the right ventricle to left ventricle (VV) interval to converge on an impedance maximum indicative of minimum cardiac volume at end systole. Another embodiment varies the VV interval to maximize impedance change. Other methods vary the AA interval to maximize impedance change over the entire cardiac cycle or during the atrial cycle.

A method for measuring ventricular dimensions from M-mode echocardiograms, includes providing a digitized M-mode echocardiogram image, running a plurality of local classifiers, where each local classifier trained to detect a landmark on either an end-diastole (ED) line or an end-systole (ES) line in the image, recording all possible landmarks detected by the classifiers, where a search range in an N-dimensional parameter space defined by the landmarks for each dimension is reduced to a union of subsets, where each dimension of the parameter space corresponds a landmark, for each combination of possible landmarks, checking if an order of the landmarks is consistent with a known ordering of the landmarks, and if the order is consistent, running a global detector on each consistent combination of landmarks to find a landmark combination with a highest detection probability as a confirmed landmark detection, where the landmarks are used for measuring ventricular dimensions.

The present invention relates to a method for determining right ventricle stroke volume comprising the steps of: providing a plurality of three-dimensional images of right cardiac ventricle of a patient over a cardiac cycle; identically slicing each of the plurality of images; selecting an image from the plurality of images, for each time unit of the cardiac cycle; determining a region of interest in each slice of the selected images, wherein the region of interest shows the right ventricle of the patient; determining area of the region of interest; determining volume of the region of interest; determining total volume of the region of interest for each time unit, wherein the maximum total volume is end diastolic volume and the minimum total volume is end systolic volume; and determining the right ventricle stroke volume using an equation:

Right Ventricle Stroke Volume=end diastolic volume−end systolic volume   (3).

The invention discloses application of atractylodin in the preparation of drugs for treating and preventing heart failure, and belongs to the field of medicine. Atractylodin can significantly increase maximum rising speed of left ventricular developed pressure and left ventricular pressure of rat isolated heart, is dependent on concentration, causes no significant effect on heart rate, and is free of adverse effect causing arrhythmia. It is indicated that atractylodin has positive inotropic action and is not dependent on neurohumor. Atractylodin can significantly increase a normal rat's end-systolic volume, end-systolic pressure, stroke volume, ejection fraction, cardiac output, left ventricular pressure maximum rising speed, stroke work, and slope of end-systolic pressure-volume relational curve. It is indicated that atractylodin has positive inotropic action without increasing heart rate.

An ultrasound imaging system is for determining stroke volume and/or cardiac output. The imaging system may include a transducer unit for acquiring ultrasound data of a heart of a subject (or an input for receiving the acquired ultrasound data), and a controller. The controller is adapted to implement a two-step procedure, the first step being an initial assessment step, and the second being an imaging step having two possible modes depending upon the outcome of the assessment. In the initial assessment procedure, it is determined whether regurgitant ventricular flow is present. This is performed using Doppler processing techniques applied to an initial ultrasound data set. If regurgitant flow does not exist, stroke volume is determined using segmentation of 3D ultrasound image data to identify and measure the volume of the left or right ventricle at each of end systole and end-diastole, the difference between them giving a measure of stroke volume. If regurgitant flow does exist, stroke volume is determined using Doppler techniques applied to ultrasound data continuously collected throughout a cardiac cycle.